Logo image of NRSN

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Fundamental Analysis

NASDAQ:NRSN - Nasdaq - IL0011809592 - Common Stock - Currency: USD

1.03  -0.01 (-0.75%)

Fundamental Rating

0

NRSN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. NRSN may be in some trouble as it scores bad on both profitability and health. NRSN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NRSN had negative earnings in the past year.
NRSN had negative earnings in each of the past 5 years.
NRSN had a negative operating cash flow in each of the past 5 years.
NRSN Yearly Net Income VS EBIT VS OCF VS FCFNRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

NRSN has a worse Return On Assets (-1061.28%) than 98.59% of its industry peers.
Industry RankSector Rank
ROA -1061.28%
ROE N/A
ROIC N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRSN Yearly ROA, ROE, ROICNRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

NRSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRSN Yearly Profit, Operating, Gross MarginsNRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NRSN has more shares outstanding
The number of shares outstanding for NRSN has been increased compared to 5 years ago.
There is no outstanding debt for NRSN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRSN Yearly Shares OutstandingNRSN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
NRSN Yearly Total Debt VS Total AssetsNRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -82.97, we must say that NRSN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NRSN (-82.97) is worse than 96.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -82.97
ROIC/WACCN/A
WACCN/A
NRSN Yearly LT Debt VS Equity VS FCFNRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NRSN has a Current Ratio of 0.21. This is a bad value and indicates that NRSN is not financially healthy enough and could expect problems in meeting its short term obligations.
NRSN has a worse Current ratio (0.21) than 96.12% of its industry peers.
A Quick Ratio of 0.21 indicates that NRSN may have some problems paying its short term obligations.
NRSN's Quick ratio of 0.21 is on the low side compared to the rest of the industry. NRSN is outperformed by 95.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
NRSN Yearly Current Assets VS Current LiabilitesNRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

NRSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.86%.
EPS 1Y (TTM)-48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRSN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.75% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.61%
EPS Next 2Y8.12%
EPS Next 3Y12.75%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRSN Yearly EPS VS EstimatesNRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRSN. In the last year negative earnings were reported.
Also next year NRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRSN Price Earnings VS Forward Price EarningsNRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRSN Per share dataNRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NRSN's earnings are expected to grow with 12.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.12%
EPS Next 3Y12.75%

More info and screens

0

5. Dividend

5.1 Amount

NRSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROSENSE THERAPEUTICS LTD

NASDAQ:NRSN (5/2/2025, 8:13:25 PM)

1.03

-0.01 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-07 2025-04-07/amc
Earnings (Next)05-28 2025-05-28
Inst Owners2.78%
Inst Owner ChangeN/A
Ins Owners21.31%
Ins Owner ChangeN/A
Market Cap24.71M
Analysts80
Price Target7.65 (642.72%)
Short Float %1.2%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.4%
Min EPS beat(2)32.6%
Max EPS beat(2)90.2%
EPS beat(4)3
Avg EPS beat(4)19.24%
Min EPS beat(4)-67.38%
Max EPS beat(4)90.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)9.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1061.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -82.97
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y4.61%
EPS Next 2Y8.12%
EPS Next 3Y12.75%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.32%
OCF growth 3YN/A
OCF growth 5YN/A